Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Joshua Schimmer has maintained an Overweight rating on Cabaletta Bio (NASDAQ:CABA) and increased the price target from $40 to $50.
November 15, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst reaffirms Overweight rating on Cabaletta Bio and raises price target to $50, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100